{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60.0","upperLimit":"81.2","value":"70.6"},{"groupId":"OG001","lowerLimit":"85.9","upperLimit":"95.3","value":"90.6"},{"groupId":"OG002","lowerLimit":"83.1","upperLimit":"97.7","value":"90.4"},{"groupId":"OG003","lowerLimit":"95.3","upperLimit":"100.0","value":"98.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"64"},{"groupId":"OG003","value":"63"}],"units":"Participants"}],"description":"PFS was defined as the time interval from date of study entry to disease progression, relapse or death due to cancer or to last follow-up. Second malignancies and deaths from causes clearly not associated with tumor progression or recurrence were censored. PFS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% CI's.","dispersionType":"95% Confidence Interval","groups":[{"description":"Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and classified as Group 3 medulloblastoma by methylation arrays","id":"OG000","title":"Group 3 Medulloblastoma"},{"description":"Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and classified as Group 4 medulloblastoma by methylation arrays","id":"OG001","title":"Group 4 Medulloblastoma"},{"description":"Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and classified as SHH medulloblastoma by methylation arrays","id":"OG002","title":"Sonic Hedgehog (SHH) Medulloblastoma"},{"description":"Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and classified as WNT medulloblastoma by methylation arrays","id":"OG003","title":"Wingless (WNT) Medulloblastoma"}],"paramType":"NUMBER","populationDescription":"355 patients were classified into one of the medulloblastoma subgroups by methylation arrays and included in this analysis; 74 were Group 3 medulloblastoma, 154 were Group 4 medulloblastoma, 64 were SHH medulloblastoma, and 63 were WNT medulloblastoma patients.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Progression-free Survival (PFS) by Molecular Subgroup Based on Methylation Arrays","type":"SECONDARY","unitOfMeasure":"Percentage probability of PFS"}